News and Announcements
Future Generation Investment Company (ASX: FGX) announces brand new Share Purchase Plan
- Published October 17, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- The Future Generation Investment Company Limited (ASX: FGX) is pleased to announce a new Share Purchase Plan (SPP).
- The SPP will be offered to existing shareholders at a fixed price.
- Shareholders will have the opportunity to acquire up to $15,000 worth of ordinary shares.
The Future Generation Investment Company Limited (ASX: FGX) is pleased to announce a new Share Purchase Plan (SPP).
The Board of Directors announced that the SPP will be offered to existing shareholders at a fixed price based on FGX’s pre-tax net tangible assets (NTA). In light of the recent equity market volatility and given the new shares will be issued on Monday, 3 December 2018, the Board believes it is in the best interests of shareholders that the SPP and Placement price will be the 31 October pre-tax NTA.
Existing shareholders will have the opportunity to acquire up to $15,000 worth of ordinary shares in FGX without incurring any brokerage fees.
The fixed SPP and Placement price will be announced on Wednesday, 14 November 2018.
Existing FXG professional investors will have the ability to take part in a Placement at the same fixed price as the SPP.
About Future Generation Investment Company (ASX: FGX)
Future Generation Investment Company (ASX: FGX) provides:
- Shareholders with exposure to the best Australian fund managers without paying management or performance fees.
- Charities primarily focused on children and youth at risk with a consistent and growing stream of annual donations.
- Fund managers with a unique opportunity to make a positive difference to Australia’s future generations
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
